Chemia Biosciences, Inc.

Chemia Biosciences, Inc. is a Pittsburgh-based corporate entity registered in SAM.gov as a self-certified small disadvantaged business specializing in advanced computational technologies for natural product discovery and drug development. The company focuses on developing innovative software and computational methods that leverage high-throughput mass spectrometry, genome mining, and metabolomics techniques to identify novel natural product small molecules with potential therapeutic applications, particularly in addressing antibiotic resistance and discovering new drug candidates.

The company has received multiple federal grants from agencies including the National Institute of General Medical Sciences (NIGMS) and the National Center for Advancing Translational Sciences (NCATS), totaling approximately $900,000 in Project Grant funding between 2023-2028. These grants support the development of sophisticated computational methods for discovering novel natural products, with specific focus areas including non-ribosomal peptides, polysaccharides, aminoglycosides, and fungal natural products. The research aims to create cloud-based software tools that can systematically identify new antimicrobial, antifungal, and anticancer compounds by analyzing complex mass spectral datasets. Chemia Biosciences collaborates with research institutions like Blumberg Institute and the University of Michigan to collect and screen microbial extracts, with the ultimate goal of developing computational technologies that can predict molecular structures of natural products encoded in microbial genomes and potentially revolutionize drug discovery processes.